Literature DB >> 29418094

Lokalisiertes prätibiales bullöses Pemphigoid bei einer Patientin unter Pembrolizumab-Therapie wegen eines metastasierten Melanoms.

Kyle T Amber1, Manuel Valdebran1, Yuxin Lu2, Sebastien De Feraudy1, Kenneth G Linden1.   

Abstract

Entities:  

Year:  2018        PMID： 29418094      PMCID： PMC6134847          DOI： 10.1111/ddg.13411_g

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN： 1610-0379            Impact factor:   5.584


× No keyword cloud information.
  12 in total

1.  Clinical features and practical diagnosis of bullous pemphigoid.

Authors:  Enno Schmidt; Rocco della Torre; Luca Borradori
Journal:  Immunol Allergy Clin North Am       Date:  2012-04-17       Impact factor: 3.479

2.  Bullous pemphigoid--a report of 86 cases from Taiwan.

Authors:  Y T Chang; H N Liu; C K Wong
Journal:  Clin Exp Dermatol       Date:  1996-01       Impact factor: 3.470

3.  Immunoblot analysis of autoantigens in localized pemphigoid and pemphigoid nodularis.

Authors:  Y Kawahara; K Matsumura; T Hashimoto; T Nishikawa
Journal:  Acta Derm Venereol       Date:  1997-05       Impact factor: 4.437

4.  Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions.

Authors:  George Jour; Isabella C Glitza; Rachel M Ellis; Carlos A Torres-Cabala; Michael T Tetzlaff; Janet Y Li; Priyadharsini Nagarajan; Auris Huen; Phyu P Aung; Doina Ivan; Carol R Drucker; Victor G Prieto; Ronald P Rapini; Anisha Patel; Jonathan L Curry
Journal:  J Cutan Pathol       Date:  2016-05-08       Impact factor: 1.587

Review 5.  A multi-hit hypothesis of bullous pemphigoid and associated neurological disease: Is HLA-DQB1*03:01, a potential link between immune privileged antigen exposure and epitope spreading?

Authors:  K T Amber; J Zikry; M Hertl
Journal:  HLA       Date:  2017-01-19       Impact factor: 4.513

6.  Collagen XVII is expressed in malignant but not in benign melanocytic tumors and it can mediate antibody induced melanoma apoptosis.

Authors:  T Krenacs; G Kiszner; E Stelkovics; P Balla; I Teleki; I Nemeth; E Varga; I Korom; T Barbai; V Plotar; J Timar; E Raso
Journal:  Histochem Cell Biol       Date:  2012-06-12       Impact factor: 4.304

7.  HLA-DQB1*0301 association with increased cutaneous melanoma risk.

Authors:  J E Lee; J D Reveille; M I Ross; C D Platsoucas
Journal:  Int J Cancer       Date:  1994-11-15       Impact factor: 7.396

Review 8.  A case report of bullous pemphigoid associated with a melanoma and review of the literature.

Authors:  Kyle T Amber; Christine M Panganiban; Dorota Korta; Sebastien de Feraudy; Kristen M Kelly; Sergei A Grando
Journal:  Melanoma Res       Date:  2017-02       Impact factor: 3.599

9.  Antibasement membrane zone antibodies in localized pretibial pemphigoid.

Authors:  T Muramatsu; T Iida; T Shirai
Journal:  Int J Dermatol       Date:  1991-06       Impact factor: 2.736

10.  Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.

Authors:  Katharina C Kähler; Jessica C Hassel; Lucie Heinzerling; Carmen Loquai; Rotraut Mössner; Selma Ugurel; Lisa Zimmer; Ralf Gutzmer
Journal:  J Dtsch Dermatol Ges       Date:  2016-07       Impact factor: 5.584
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.